Update
Tempus Expands Agreement with MRNA and MRK
Tempus has extended its multi-year pact with MRNA and MRK to include support for autogeneic intismeran, a potential therapy with patient-linked sequencing and sample logistics. The agreement strengthens Tempus' role in therapy design and manufacture.